Navigation Links
Pharmion Corporation Announces 2007 Operating Results
Date:2/19/2008

rm Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Pharmion's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include the outcome of ongoing clinical trials, the status and timing or regulatory approvals for Pharmion's product candidates; the impact of competition from other products under development by Pharmion's competitors; the regulatory environment and changes in the health policies and structure of various countries; uncertainties regarding market acceptance of products newly launched, currently being sold or in development; Pharmion's ability to successfully acquire rights to, develop and commercialize additional pharmaceutical products; failure of third-party manufacturers to produce the product volumes required on a timely basis, fluctuations in currency exchange rates, and other factors that are discussed in Pharmion's filings with the U.S. Securities and Exchange Commission, including those discussed in the "Risk Factors" section of Pharmion's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

PHARMION CORPORATION

CONSOLIDATED FINANCIAL RESULTS

(In thousands, except for per share amounts)

Unaudited

Three Months Ended Twelve Months Ended<
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmion Corporation to Announce Third Quarter 2007 Financial Results
2. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
3. Pharmion Corporation to Present at Bear Stearns 2007 Healthcare Conference
4. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
5. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
6. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
7. VLST Corporation Announces Board and Executive Management Appointments
8. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
9. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
10. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... July 10, 2014 Robert Harman, DVM, Founder ... company, is proud to announce the relaunch of his highly ... a new series called “ What are Stem Cells ?” ... honest and straightforward foundation in the basics of stem cell ... on the right type of treatment when considering regenerative medicine. ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has ... now comes with a second treatment cup to help prevent ... new cup is thinner on the edges for a softer ... thin and uneven surfaces on the face, neck and décolleté. ... treatment on areas such as the cheeks and neck, or ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... Advanced Technology Drives Ongoing Live-Cell Research, ... Inc., (http://www.nikoninstruments.com ) and Northwestern University,s Feinberg ... collaborative core microscopy imaging,center, establishing a partnership ... providing critical feedback for Nikon,product development. One ...
... ExonHit Therapeutics, a drug,and diagnostic company, today ... on July 1st as Chief Operating Officer. At ... be appointed CEO (President du,Directoire)., Laurent Condomine, ... to have Loic Maurel joining ExonHit Therapeutics. His,experience ...
... infected with HIV the virus infects cells in the ... Although this causes no immediate problems, during the late-stages ... inflammation of the brain that can cause death). Monkeys ... develop CNS damage and provide a good model of ...
Cached Biology Technology:Nikon Instruments Opens New Imaging Center at Northwestern University 2Nikon Instruments Opens New Imaging Center at Northwestern University 3Loic Maurel Joins Exonhit Therapeutics to Become CEO 2Loic Maurel Joins Exonhit Therapeutics to Become CEO 3Loic Maurel Joins Exonhit Therapeutics to Become CEO 4
(Date:7/11/2014)... receptor type 1 can inhibit voltage-gated calcium ... neurotransmitter release. However, some scholars demonstrated that ... Ca2+ influx and increase neurotransmitter release. Dr. ... Affiliated to Tongji Medical College, Huazhong University ... cell voltage-clamp and calcium imaging in cultured ...
(Date:7/11/2014)... toxins to study the proteins that let nerve cells ... have stumbled upon a biological tactic that may offer ... in a safe and environmentally responsible way. , ... for one species and harmless for a closely related ... pests without harming beneficial species like bees. A summary ...
(Date:7/10/2014)... other major cities in New Mexico, nearly every public ... rather than precious potable water supplies. Across the U.S. ... golf courses receive treated effluent. Reusing the effluent increases ... courses and homeowners alike fertilize their lawns during the ... A New Mexico State University turfgrass expert has a ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3'Tailored' water -- the latest in lawn care 2
... the saliva of the Gila monster lizard is effective ... Sahlgrenska Academy, University of Gothenburg, have tested the drug ... both food and chocolate. An increasing number of ... pharmaceutical preparation called Exenatide, which helps them to control ...
... reporting estimates of the prevalence of sexually transmitted infections/reproductive ... years suggests that a considerable burden of malaria and ... facilities in sub-Saharan Africa, according to a review and ... issue of JAMA , a theme issue on ...
... of tiger snakes stranded for thousands of years on tiny ... nearly twice the size of their mainland cousins. Now, new ... enormity of these elapids was driven by the need to ... out at 35 inches (89 cm) long, patrol swampy areas ...
Cached Biology News:Drugs from lizard saliva reduces the cravings for food 2Considerable prevalence of both malaria, STIs exist among pregnant women in sub-Saharan Africa 2Big-mouthed babies drove the evolution of giant island snakes 2Big-mouthed babies drove the evolution of giant island snakes 3
... Materials for 15-20 enhancements ... TM Western Blot Signal Enhancement System is designed ... and is an excellent tool for evaluating proteins with ... used to pre-treat membrane prior to blocking the membrane; ...
... CHEMICON Re-Blot Western Blot Recycling Kit ... from Western blots that have been ... or other isotopes. It is not ... DAB, 4-chloronapthol, etc.), as it is ...
... to siRNA library screening, optimal ... identified and verified for each ... CellReady siRNA Transfection Optimization Kit, ... optimizing transfection conditions in 96 ...
... Immulon ... surface to provide increased binding affinity ... Flat bottom works well for ... optical characteristics., Each ...
Biology Products: